Anna Burgner, MD
Nephrology · Nashville, TNNPI 1548464027
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,950 of the $10,987 with a category attached, or 99.7%. Bayer accounts for 99.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $6,000 and has fallen 99.9% since, to $3 in 2024.
Across 16 payments — averaging $686.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$11K
- Travere Therapeutics, Inc.$25
- Vifor Pharma, Inc.$12
Across 211 payments — averaging $3682.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$678K
- AstraZeneca$66K
- CSL Behring$34K
What the payments were for
- Consulting fees$10,950100%
- Education$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 7 | $10,950 |
| Travere Therapeutics, Inc. | 8 | $25 |
| Vifor Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered$9,450
- Kerendia$1,500
How this compares
$10,987 in reported general payments places this provider in the 85th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 13 | $246,948 |
| AranespDarbepoetin Alfa In Polysorbat | 23 | $69,182 |
| JardianceEmpagliflozin | 20 | $32,611 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $30,342 |
| FarxigaDapagliflozin Propanediol | 20 | $26,904 |
| Sevelamer Carbonate | 34 | $6,477 |
| Mycophenolate Mofetil | 13 | $6,285 |
| RetacritEpoetin Alfa-Epbx | 17 | $4,710 |
| Calcium Acetate | 53 | $3,259 |
| Nifedipine ErNifedipine | 69 | $3,082 |
| Potassium Chloride | 56 | $1,809 |
| Potassium Citrate ErPotassium Citrate | 22 | $1,595 |
| Losartan Potassium | 71 | $980 |
| Bumetanide | 14 | $906 |
| Gentamicin Sulfate | 62 | $817 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Nashville
- Jamie DwyerNashville$461K
- Volker HaaseNashville$123K
- Talat IkizlerNashville$93K
- Julia LewisNashville$87K
- Osama El ShamyNashville$87K
- Thomas GolperNashville$26K
- Anthony LangoneNashville$23K
- James LutherNashville$20K
- Jeffrey HymesNashville$19K
- Roy ZentNashville$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.